News Centre

 
Home ... News Centre ... Press Releases

Press Releases


Panmure Gordon is Appointed as Nominated Adviser and Broker
Released 6th December 2007


Interim Results for Six Months Ended 31 July 2007
Released 30th October 2007


Summit Sign $450,000 Zebrafish Deal with a Top Five Pharmaceutical Company
Released 30th October 2007


Phase I Clinical Trial in Parkinson's disease and Acne programme commences
Released 23rd October 2007


Summit receives £220,000
Released 2nd October 2007


Summit Presents Zebrafish Data
Released 24th September 2007


Zebrafish data supports MHRA Application
Released 8th August 2007


$10 Million Collaboration Deal in Infectious Diseases Signed
Released 24th July 2007
Collaboration with European biotechnology company Evolva.


Summit plc is the New Name for VASTox plc
Released 20th July 2007


Results of Annual General Meeting
Released 19th July 2007


VASTox Announces Significant Progress in Pharmaceutical Services Business
Released 27th June 2007
Pilot screening deals signed with Merck and J&J plus construction of GMP carbohydrate chemistry facility completed.


VASTox Receives Grant Worth £400,000 to Support R&D at Carbohydrate Chemistry Facility
Released 20th June 2007


VASTox Prepares to Commence the Next Stage of Clinical Trials in Parkinson's Programmes
Released 29th May 2007


VASTox Signs Carbohydrate Service Deal which Includes $450,000 Development Payment and 5% Royalty Fee
Released 16th May 2007


VASTox Selects Preclinical Candidate in Duchenne Muscular Dystrophy Programme
Released 8th May 2007
SUMM C1100 selected as candidate to advance into preclinical development.


VASTox to Present Data from Duchenne Muscular Dystrophy Programme at Conference
Released 30th April 2007


VASTox Announce Positive Results in TB Programme
Released 25th April 2007
VASTox identifies novel compounds that kill tuberculosis bacteria.


VASTox Appoints George Elliott to the Board of Directors
Released 23rd April 2007


VASTox Consolidate Market Dominance in Zebrafish Chemical Genomics Following the Granting of a Key Patent
Released 17th April 2007
VASTox granted a European patent that increases the value of the zebrafish chemical genomics technology platform.


Patent Granted in the US to Strengthen DMD Programme
Released 12th April 2007
VASTox's unique approach to treating DMD has been further protected by the award of this patent by the US Patent Office.


Major Pharmaceutical Companies Present VASTox Scientific Data at International Conference
Released 27th March 2007
Roche, Bayer-Schering and Merz present predictive toxicology data acquired using VASTox's zebrafish technology platform.


VASTox Complete the Simultaneous Acquisitions of DanioLabs Ltd and Dextra Laboratories Ltd
Released 22nd March 2007
Drug discovery pipeline enhanced through acquisitions and VASTox becomes world dominant in two drug discovery technology platforms.


VASTox plc raise £10.45 million through the issue of new ordinary shares
Released 27th February 2007


VASTox Sign Two Research Collaboration Deals Worth a Combined Total of €1.0 Million
Released 13th February 2007


Pre-close Trading Statement
Released 30th January 2007


VASTox Joins Research Consortium to Develop New Treatments for Cancer
Released 17th January 2007
Research consortium backed by €2 million grant from the European Commission to focus on cancer stem cells as target for the development of new therapies.